309 related articles for article (PubMed ID: 17426942)
21. Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia.
Joo KJ; Sung WS; Park SH; Yang WJ; Kim TH
J Int Med Res; 2012; 40(3):899-908. PubMed ID: 22906262
[TBL] [Abstract][Full Text] [Related]
22. Benign prostatic hyperplasia progression and its impact on treatment.
Djavan B; Waldert M; Ghawidel C; Marberger M
Curr Opin Urol; 2004 Jan; 14(1):45-50. PubMed ID: 15091050
[TBL] [Abstract][Full Text] [Related]
23. [Drug therapy for benign prostatic syndrome (BPS)].
Berges R
Aktuelle Urol; 2006 Sep; 37(5):351-62. PubMed ID: 17004180
[TBL] [Abstract][Full Text] [Related]
24. [REVIEW OF CLINICAL STUDIES ON COMBINATION THERAPY OF 5α-REDUCTASE INHIBITORS AND α1-BLOCKERS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA].
Spivak LG; Lokshin KL; Vinarov AZ
Urologiia; 2015; (4):125-33. PubMed ID: 26665780
[TBL] [Abstract][Full Text] [Related]
25. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
26. [Epidemiology of BPH and medication approaches].
Marszalek M; Madersbacher S
Ther Umsch; 2006 Feb; 63(2):123-8. PubMed ID: 16514964
[TBL] [Abstract][Full Text] [Related]
27. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
Roehrborn CG
BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
[TBL] [Abstract][Full Text] [Related]
28. [Drug therapy of benign prostatic hyperplasia].
Vahlensieck W; Fabricius PG; Hell U
Fortschr Med; 1996 Nov; 114(31):407-11. PubMed ID: 9036092
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia.
Choi JD; Yoo TK; Kang JY; Jung HD; Lee JH
Int Urol Nephrol; 2023 Apr; 55(4):845-851. PubMed ID: 36763223
[TBL] [Abstract][Full Text] [Related]
30. Long-term results of medical treatment in benign prostatic hyperplasia.
Kim CI; Chang HS; Kim BK; Park CH
Urology; 2006 Nov; 68(5):1015-9. PubMed ID: 17095071
[TBL] [Abstract][Full Text] [Related]
31. The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH.
Sountoulides P; Gravas S
Curr Drug Targets; 2015; 16(11):1172-9. PubMed ID: 25706255
[TBL] [Abstract][Full Text] [Related]
32. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study.
Wada N; Kita M; Hashizume K; Matsumoto S; Kakizaki H
Neurourol Urodyn; 2013 Nov; 32(8):1123-7. PubMed ID: 23861329
[TBL] [Abstract][Full Text] [Related]
33. Real-world use of Permixon® in benign prostatic hyperplasia--determining appropriate monotherapy and combination treatment.
Perry R; Milligan G; Anderson P; Gillon A; White M
Adv Ther; 2012 Jun; 29(6):538-50. PubMed ID: 22644964
[TBL] [Abstract][Full Text] [Related]
34. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
Kaplan SA
J Urol; 2005 Sep; 174(3):1011. PubMed ID: 16094031
[No Abstract] [Full Text] [Related]
35. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
[TBL] [Abstract][Full Text] [Related]
36. [Established and upcoming new options in medical therapy for benign prostatic hyperplasia].
Schlenker B; Beer AM; Gratzke C; Tilki D; Seitz M; Stief CG; Reich O
MMW Fortschr Med; 2009 Oct; 151(41):33-6. PubMed ID: 19891182
[No Abstract] [Full Text] [Related]
37. [Importance of adrenoceptor blockers and alpha reductase inhibitors : Monotherapy for treatment of benign prostate syndrome].
Strittmatter F; Madersbacher S; Stief CG; Gratzke C
Urologe A; 2013 Feb; 52(2):197-203. PubMed ID: 23370402
[TBL] [Abstract][Full Text] [Related]
38. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
39. 5-Alpha-Reductase Inhibitors and Combination Therapy.
Füllhase C; Schneider MP
Urol Clin North Am; 2016 Aug; 43(3):325-36. PubMed ID: 27476125
[TBL] [Abstract][Full Text] [Related]
40. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
